Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis

Inflammasome is a cytoplasmic multiprotein complex that facilitates the clearance of exogenous microorganisms or the recognition of endogenous danger signals, which is critically involved in innate inflammatory response. Excessive or abnormal activation of inflammasomes has been shown to contribute...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 816839
Main Authors Jiang, Qi, Wang, Xin, Huang, Enyu, Wang, Qiao, Wen, Chengping, Yang, Guocan, Lu, Liwei, Cui, Dawei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 13.01.2022
Subjects
Animals
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - etiology
Arthritis, Rheumatoid - metabolism
Autoimmunity
Biomarkers
Disease Management
Disease Susceptibility
Genetic Predisposition to Disease
Humans
Immunology
immunotherapy
inflammasome
Inflammasomes - immunology
Inflammasomes - metabolism
inflammation
Molecular Targeted Therapy
Polymorphism, Single Nucleotide
rheumatoid arthritis
autoimmunity
inflammation
rheumatoid arthritis
inflammasome
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Inflammasome is a cytoplasmic multiprotein complex that facilitates the clearance of exogenous microorganisms or the recognition of endogenous danger signals, which is critically involved in innate inflammatory response. Excessive or abnormal activation of inflammasomes has been shown to contribute to the development of various diseases including autoimmune diseases, neurodegenerative changes, and cancers. Rheumatoid arthritis (RA) is a chronic and complex autoimmune disease, in which inflammasome activation plays a pivotal role in immune dysregulation and joint inflammation. This review summarizes recent findings on inflammasome activation and its effector mechanisms in the pathogenesis of RA and potential development of therapeutic targeting of inflammasome for the immunotherapy of RA.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors have contributed equally to this work
Edited by: Elias Toubi, Technion Israel Institute of Technology, Israel
This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology
Reviewed by: Pawel Paszek, The University of Manchester, United Kingdom; Anna Lisa Giuliani, University of Ferrara, Italy
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.816839